324 related articles for article (PubMed ID: 26400460)
1. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.
Brown AL; Lupo PJ; Okcu MF; Lau CC; Rednam S; Scheurer ME
Cancer Med; 2015 Nov; 4(11):1679-86. PubMed ID: 26400460
[TBL] [Abstract][Full Text] [Related]
2. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
[TBL] [Abstract][Full Text] [Related]
3. Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma.
Rednam S; Scheurer ME; Adesina A; Lau CC; Okcu MF
Pediatr Blood Cancer; 2013 Apr; 60(4):593-8. PubMed ID: 23065688
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
5. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
Knight KR; Kraemer DF; Neuwelt EA
J Clin Oncol; 2005 Dec; 23(34):8588-96. PubMed ID: 16314621
[TBL] [Abstract][Full Text] [Related]
6. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies.
Al-Serri A; Anstee QM; Valenti L; Nobili V; Leathart JB; Dongiovanni P; Patch J; Fracanzani A; Fargion S; Day CP; Daly AK
J Hepatol; 2012 Feb; 56(2):448-54. PubMed ID: 21756849
[TBL] [Abstract][Full Text] [Related]
7. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.
Barahmani N; Carpentieri S; Li XN; Wang T; Cao Y; Howe L; Kilburn L; Chintagumpala M; Lau C; Okcu MF
Neuro Oncol; 2009 Jun; 11(3):292-300. PubMed ID: 18952980
[TBL] [Abstract][Full Text] [Related]
8. The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms.
Liu G; Zhou W; Park S; Wang LI; Miller DP; Wain JC; Lynch TJ; Su L; Christiani DC
Cancer; 2004 Dec; 101(12):2802-8. PubMed ID: 15534883
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG; Bass JK; Onar-Thomas A; Huang J; Chintagumpala M; Bouffet E; Hassall T; Gururangan S; Heath JA; Kellie S; Cohn R; Fisher MJ; Panandiker AP; Merchant TE; Srinivasan A; Wetmore C; Qaddoumi I; Stewart CF; Armstrong GT; Broniscer A; Gajjar A
Neuro Oncol; 2014 Jun; 16(6):848-55. PubMed ID: 24414535
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
[TBL] [Abstract][Full Text] [Related]
11. Association between manganese superoxide dismutase polymorphism and risk of lung cancer.
Zejnilovic J; Akev N; Yilmaz H; Isbir T
Cancer Genet Cytogenet; 2009 Feb; 189(1):1-4. PubMed ID: 19167605
[TBL] [Abstract][Full Text] [Related]
12. A prospective study on associations between superoxide dismutase gene polymorphisms and antituberculosis drug-induced liver injury in a Chinese Han population.
Wu T; Bai H; Zhao Z; Wang M; Hu X; Jiao L; Wu Q; Liu T; Zhang C; Chen H; Zhang J; Song J; Wu L; Zhou W; Tong C; Ying B
J Gene Med; 2019 Oct; 21(10):e3121. PubMed ID: 31415712
[TBL] [Abstract][Full Text] [Related]
13. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility.
Kocabaş NA; Sardaş S; Cholerton S; Daly AK; Elhan AH; Karakaya AE
Cell Biochem Funct; 2005; 23(1):73-6. PubMed ID: 15386537
[TBL] [Abstract][Full Text] [Related]
15. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.
Riedemann L; Lanvers C; Deuster D; Peters U; Boos J; Jürgens H; am Zehnhoff-Dinnesen A
Pharmacogenomics J; 2008 Feb; 8(1):23-8. PubMed ID: 17457342
[TBL] [Abstract][Full Text] [Related]
16. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.
Lafay-Cousin L; Purdy E; Huang A; Cushing SL; Papaioannou V; Nettel-Aguirre A; Bouffet E
Pediatr Blood Cancer; 2013 Feb; 60(2):287-92. PubMed ID: 23002030
[TBL] [Abstract][Full Text] [Related]
17. Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients.
Olgun Y; Aktaş S; Altun Z; Kırkım G; Kızmazoğlu DÇ; Erçetin AP; Demir B; İnce D; Mutafoğlu K; Demirağ B; Ellidokuz H; Olgun N; Güneri EA
Int J Pediatr Otorhinolaryngol; 2016 Nov; 90():64-69. PubMed ID: 27729156
[TBL] [Abstract][Full Text] [Related]
18. Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer.
Arsova-Sarafinovska Z; Matevska N; Petrovski D; Banev S; Dzikova S; Georgiev V; Sikole A; Sayal A; Aydin A; Suturkova L; Dimovski AJ
Cell Biochem Funct; 2008 Oct; 26(7):771-7. PubMed ID: 18646267
[TBL] [Abstract][Full Text] [Related]
19. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
20. The genetic vulnerability to cisplatin ototoxicity: a systematic review.
Tserga E; Nandwani T; Edvall NK; Bulla J; Patel P; Canlon B; Cederroth CR; Baguley DM
Sci Rep; 2019 Mar; 9(1):3455. PubMed ID: 30837596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
